61 related articles for article (PubMed ID: 3937579)
1. Deflazacort. A review of its pharmacological properties and therapeutic efficacy.
Markham A; Bryson HM
Drugs; 1995 Aug; 50(2):317-33. PubMed ID: 8521761
[TBL] [Abstract][Full Text] [Related]
2. Effects of deflazacort versus prednisone on bone mass, body composition, and lipid profile: a randomized, double blind study in kidney transplant patients.
Lippuner K; Casez JP; Horber FF; Jaeger P
J Clin Endocrinol Metab; 1998 Nov; 83(11):3795-802. PubMed ID: 9814449
[TBL] [Abstract][Full Text] [Related]
3. Skeletal Muscle Response to Deflazacort, Dexamethasone and Methylprednisolone.
Fappi A; Neves JC; Sanches LN; Massaroto E Silva PV; Sikusawa GY; Brandão TPC; Chadi G; Zanoteli E
Cells; 2019 May; 8(5):. PubMed ID: 31052442
[TBL] [Abstract][Full Text] [Related]
4. The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy.
McAdam LC; Mayo AL; Alman BA; Biggar WD
Acta Myol; 2012 May; 31(1):16-20. PubMed ID: 22655512
[TBL] [Abstract][Full Text] [Related]
5. The pituitary-adrenal axis and body composition.
Fernandez-Rodriguez E; Stewart PM; Cooper MS
Pituitary; 2009; 12(2):105-15. PubMed ID: 18324475
[TBL] [Abstract][Full Text] [Related]
6. CGRP receptors mediating CGRP-, adrenomedullin- and amylin-induced relaxation in porcine coronary arteries. Characterization with 'Compound 1' (WO98/11128), a non-peptide antagonist.
Hasbak P; Sams A; Schifter S; Longmore J; Edvinsson L
Br J Pharmacol; 2001 Aug; 133(8):1405-13. PubMed ID: 11498528
[TBL] [Abstract][Full Text] [Related]
7. Corticosteroid-induced bone loss. Prevention and management.
Picado C; Luengo M
Drug Saf; 1996 Nov; 15(5):347-59. PubMed ID: 8941496
[TBL] [Abstract][Full Text] [Related]
8. Changes in bone mass during low dose corticosteroid treatment in patients with polymyalgia rheumatica: a double blind, prospective comparison between prednisolone and deflazacort.
Krogsgaard MR; Thamsborg G; Lund B
Ann Rheum Dis; 1996 Feb; 55(2):143-6. PubMed ID: 8712867
[TBL] [Abstract][Full Text] [Related]
9. Comparative study of the effects of different glucocorticosteroids on eosinophil survival primed by cultured epithelial cell supernatants obtained from nasal mucosa and nasal polyps.
Mullol J; Xaubet A; López E; Roca-Ferrer J; Picado C
Thorax; 1995 Mar; 50(3):270-4. PubMed ID: 7660341
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of glucocorticoids on human osteoblastic cell metabolism in vitro.
Kasperk C; Schneider U; Sommer U; Niethard F; Ziegler R
Calcif Tissue Int; 1995 Aug; 57(2):120-6. PubMed ID: 7584872
[TBL] [Abstract][Full Text] [Related]
11. Serum osteocalcin (bone Gla-protein) following corticosteroid therapy in postmenopausal women with rheumatoid arthritis. Comparison of the effect of prednisone and deflazacort.
Montecucco C; Baldi F; Fortina A; Tomassini G; Caporali R; Cherie-Ligniere EL; Fratino P
Clin Rheumatol; 1988 Sep; 7(3):366-71. PubMed ID: 3265902
[TBL] [Abstract][Full Text] [Related]
12. Reduced strength of rat cortical bone after glucocorticoid treatment.
Ortoft G; Oxlund H
Calcif Tissue Int; 1988 Dec; 43(6):376-82. PubMed ID: 3146427
[TBL] [Abstract][Full Text] [Related]
13. Establishment of the relative antiinflammatory potency of deflazacort and prednisone in polymyalgia rheumatica.
Lund B; Egsmose C; Jørgensen S; Krogsgaard MR
Calcif Tissue Int; 1987 Dec; 41(6):316-20. PubMed ID: 3124940
[TBL] [Abstract][Full Text] [Related]
14. Vertebral collapse in juvenile chronic arthritis: its relationship with glucocorticoid therapy.
Varonos S; Ansell BM; Reeve J
Calcif Tissue Int; 1987 Aug; 41(2):75-8. PubMed ID: 3115548
[TBL] [Abstract][Full Text] [Related]
15. Drug-induced rheumatic syndromes. Diagnosis, clinical features and management.
Cohen MG; Prowse MV
Med Toxicol Adverse Drug Exp; 1989; 4(3):199-218. PubMed ID: 2490148
[TBL] [Abstract][Full Text] [Related]
16. Comparison of growth retarding effects induced by two different glucocorticoids in prepubertal sick children: an interim long-term analysis.
Aicardi G; Milani S; Imbimbo B; Vignolo M; Di Battista E; Gusmano R; Terragna A; Cordone G; Cottafava F; Coppo R
Calcif Tissue Int; 1991 Apr; 48(4):283-7. PubMed ID: 2059880
[TBL] [Abstract][Full Text] [Related]
17. Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: a double-blind study on the high-dose, long-term effects of prednisone versus deflazacort.
Olgaard K; Storm T; van Wowern N; Daugaard H; Egfjord M; Lewin E; Brandi L
Calcif Tissue Int; 1992 Jun; 50(6):490-7. PubMed ID: 1525702
[TBL] [Abstract][Full Text] [Related]
18. Effects of prednisone and deflazacort on vertebral bone mass.
Gennari C; Imbimbo B
Calcif Tissue Int; 1985 Dec; 37(6):592-3. PubMed ID: 3937579
[TBL] [Abstract][Full Text] [Related]
19. A histomorphometric long-term longitudinal study of trabecular bone loss in glucocorticoid-treated patients: prednisone versus deflazacort.
LoCascio V; Ballanti P; Milani S; Bertoldo F; LoCascio C; Zanolin EM; Bonucci E
Calcif Tissue Int; 1998 Mar; 62(3):199-204. PubMed ID: 9501951
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
